肿瘤免疫检查点抑制剂的临床不良反应及处理策略  

Clinical adverse reactions and treatment strategies of tumor immune checkpoint blockades

作　　者：汪婷婷 罗琴 袁向亮[1] 沈立松[1] WANG Tingting;LUO Qin;YUAN Xiangliang;SHEN Lisong(Department of Clinical Laboratory, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, Chin)

机构地区：[1]上海交通大学医学院附属新华医院检验科,上海200092

出　　处：《肿瘤》2018年第2期164-172,共9页Tumor

摘　　要：以细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte-associated antigen-4,CTLA-4)和免疫检查点程序性死亡分子1(programmed death-1,PD-1)/程序性死亡分子配体1(programmed death-ligand 1,PD-L1)抗体为代表的免疫检查点抑制剂(immune checkpoint blockade,ICB)作为一种新型恶性肿瘤治疗药物,在临床上对多种肿瘤都具有良好的治疗效果。然而,这些药物也可产生广泛的免疫相关性不良反应,迫使患者中止治疗,甚至影响患者生存。因此,随着ICB在临床上的广泛应用,临床医生需要充分认识肿瘤ICB治疗可能产生的不良反应以及适当的治疗策略,以提高ICB治疗患者的生存率和治疗效果。As representatives of immune checkpoint antibodies targeting cytotoxic T-lymphocyte ant blockades （ICBs）, gen-4 （CTLA-4） and programmed cell death-1 （PD-1）/programmed death-ligand 1 （PD-L1） have significantly improved the treatment efficacies of a variety of malignant tumors. However, ICBs can also produce a wide range of immune-related adverse reactions, forcing patients to stop treatment and even affect the survival of the patients. Therefore, with the wide application of ICBs in clinical practice, clinical oncologists need to fully understand the possible side effects of ICBs therapy and the appropriate treatment strategies to improve the survival rate and therapeutic effect of patients receiving ICBs.

关 键 词：肿瘤 肿瘤治疗方案 细胞毒性T淋巴细胞相关抗原4 程序性死亡分子1 药物相关性副作用及不良反应 

分 类 号：R730.3[医药卫生—肿瘤]